Table 1. Ongoing clinical trials for Alzheimer disease.

Company	Vaccine	Composition	Adjuvant	Trial phase	References
Novartis	CAD106	Aβ1–6 on Qβ VLP	VLP; VLP/Alum; VLP/MF59	Phase III	32
AFFiRiS AG	AD02/AD03	Aβ1–6 Mimatope + carrier	Alum	Phase II	33
Pfizer/J&J	ACC-001	Aβ1–6 + carrier CRM197	QS-21	Phase II	10, 23, 24
Merck	V950	N-terminal region from Aβ1–42	ISCOMATRIX; ISCOMATRIX+Alum	Phase II	10, 23, 24
United Biomedical	UB-311	Aβ1–14 + T cell epitope from MVF, HBVsa, PT, TT.	CpG+Alum	Phase II	10, 23, 24
AC Immune	ACI-24	Aβ1–15 on a liposome membrane	Liposome and MPLA inside the liposome	Phase I/II	10, 26, 27